Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by
Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …

The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants with spike protein mutations raises concerns that antibodies elicited by natural …

Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

Background The emergence of new SARS-CoV-2 variants of concern B. 1.1. 7 (Alpha), B.
1.351 (Beta), P. 1 (Gamma) and B. 1.617. 2 (Delta) that harbor mutations in the viral S …

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show
protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the …

All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of
generating protective neutralizing antibodies. The recent emergence and rapid spread of …

One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …

The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2,
continues to rage. Prospects of ending this pandemic rest on the development of effective …